Posted by Michael Wonder on 16 Jul 2020
Mallinckrodt and Terumo BCT announce positive recommendations for public funding of Uvadex (methoxsalen) for ECP administration with the Therakos CE
13 July 2020 - In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement based on a favourable clinical and cost-effectiveness comparison.
Mallinckrodt and Terumo BCT announced today that both the Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC) recently recommended that Uvadex (methoxsalen) for extracorporeal administration with the Therakos Cellex Photopheresis System be listed on the Pharmaceutical Benefits Scheme in Australia for the treatment of cutaneous T-cell lymphoma in adults.
In this two part evaluation, the PBAC supported the cost-effectiveness of Uvadex, the pharmaceutical component of the treatment system; and the MSAC accepted the claim of superiority for safety and non-inferiority for efficacy between extracorporeal administration with Uvadex and three comparators.
